GKOS GLAUKOS Corp
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1192448 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY46.9%
TTM net income YoY-93.8%
TTM EPS YoY-91.6%
Revenue 3-yr CAGR31.5%
Net income 3-yr CAGR—
Margins
Gross margin64.8%
Operating margin-25.5%
Net margin-24.6%
FCF margin5.2%
EBITDA margin-19.5%
Returns
ROE-22.8%
ROA-17.2%
ROIC (approx.)-22.8%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets26.8%
Debt / equity0.00x
Current ratio4.57x
Interest coverage-36.57x
Cash quality & payout
Operating cash flow / net income-0.28x
Accruals ratio-22.0%
Payout ratio—
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $211.03M | $185.61M | $150.57M | $143.12M | $133.54M | $124.12M | $106.66M | $105.50M |
| Cost of revenue | $31.16M | $34.02M | $33.34M | $31.77M | $28.83M | $26.90M | $24.32M | $28.64M |
| Gross profit | $179.87M | $151.59M | $117.23M | -$1.52M | $104.71M | $97.22M | $82.35M | $76.86M |
| R&D expense | $30.95M | $51.30M | $44.15M | $43.65M | $26.86M | $36.54M | $32.35M | $36.53M |
| SG&A expense | $130.94M | $116.06M | $92.94M | $94.70M | $83.00M | $83.38M | $70.67M | $69.00M |
| Operating income | $828,000 | -$17.27M | -$19.86M | -$139.87M | -$16.36M | -$22.69M | -$20.68M | -$28.67M |
| Interest expense | $1.09M | $1.46M | $1.12M | $1.15M | $1.18M | $1.15M | $1.16M | $1.57M |
| Pretax income | $2.32M | -$17.72M | -$19.30M | -$139.82M | -$16.00M | -$19.41M | -$17.82M | -$33.69M |
| Income tax | $303,000 | $656,000 | $484,000 | -$6.16M | $234,000 | $248,000 | $326,000 | -$114,000 |
| Net income | $2.02M | -$18.38M | -$19.78M | -$133.66M | -$16.23M | -$19.66M | -$18.15M | -$33.58M |
| EBITDA | $9.78M | -$8.40M | -$8.06M | -$127.70M | -$7.23M | -$14.12M | -$12.45M | -$19.93M |
| EPS (basic) | 0.03 | -0.31 | -0.34 | — | -0.28 | -0.34 | -0.32 | — |
| EPS (diluted) | 0.03 | -0.31 | -0.34 | — | -0.28 | -0.34 | -0.32 | — |
| Weighted avg. shares (diluted) | 61.20M | 58.82M | 58.02M | — | 57.40M | 57.20M | 56.64M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $162.33M | $114.48M | $104.25M | $90.81M | $102.08M | $104.65M | $118.98M | $174.36M |
| Receivables | $150.00M | $138.90M | $119.69M | $108.61M | $98.68M | $82.98M | $71.53M | $60.74M |
| Inventory | $61.03M | $59.31M | $62.38M | $63.56M | $63.86M | $64.62M | $59.46M | $57.68M |
| Current assets | $579.65M | $515.78M | $485.75M | $474.98M | $454.77M | $436.06M | $444.54M | $449.79M |
| PP&E, net | $112.07M | $112.11M | $112.43M | $113.25M | $110.94M | $111.82M | $96.81M | $97.87M |
| Goodwill | $66.71M | $66.71M | $66.71M | $66.71M | $66.71M | $66.71M | $66.13M | $66.13M |
| Intangibles | $121.26M | $127.15M | $133.03M | $141.92M | $264.14M | $270.49M | $257.87M | $263.44M |
| Total assets | $979.53M | $920.52M | $893.33M | $893.49M | $999.38M | $986.96M | $966.18M | $974.76M |
| Current liabilities | $126.73M | $102.33M | $89.42M | $101.28M | $87.52M | $79.14M | $68.53M | $75.12M |
| Total liabilities | $262.25M | $238.03M | $222.40M | $237.33M | $229.84M | $221.85M | $202.22M | $207.82M |
| Shareholders' equity | $717.27M | $682.49M | $670.93M | $656.15M | $769.54M | $765.11M | $763.96M | $766.93M |
| Shares outstanding | 59.17M | 58.86M | 58.36M | 57.51M | 57.39M | 57.25M | 56.74M | 56.44M |
| Cash flow statement | ||||||||
| Operating cash flow | $38.57M | $14.82M | -$12.53M | $6.84M | -$10.09M | $6.98M | -$18.52M | $507,000 |
| Capital expenditure | $2.08M | $2.74M | $3.96M | $2.91M | $1.64M | $1.18M | $1.94M | $1.73M |
| Free cash flow | $36.49M | $12.09M | -$16.48M | $3.93M | -$11.72M | $5.80M | -$20.46M | -$1.23M |
| Investing cash flow | -$5.54M | -$5.31M | $10.50M | -$15.89M | -$3.99M | -$20.78M | -$36.95M | $11.79M |
| Financing cash flow | $14.69M | $991,000 | $15.77M | $2.43M | $5.26M | $2.25M | $1.95M | $60.11M |
| Depreciation & amortization | $8.95M | $8.87M | $11.80M | $12.16M | $9.13M | $8.57M | $8.23M | $8.74M |
| Stock-based compensation | $17.77M | $28.86M | $19.14M | $17.30M | $14.91M | $18.02M | $12.99M | $13.31M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.